治疗抑郁症症状的肌酸补充剂:一个系统的审查和元分析
Igor Eckert1, Júlia Lima2, Andressa Amaral Dariva3
1Independent Scholar, Porto Alegre, RS, Brazil.
The British journal of nutrition
|November 5, 2025
概括
肌酸补充剂可能对抑郁症症状有很小的益处,但这些效应在临床上并不显著,而且证据非常不确定. 需要更严格的试验来确认任何潜在的益处.
科学领域:
- 营养精神病学是一种精神病学.
- 神经科学是一个神经科学.
- 补充研究研究 补充研究
背景情况:
- 营养药在营养精神病学中越来越受到关注.
- 肌酸已在随机试验中研究其对抑郁症状的影响.
- 以前关于治疗抑郁症的肌酸的发现缺乏系统的合成.
研究的目的:
- 系统地审查和综合肌酸补充剂对抑郁症症状的影响.
- 评估克reatine在治疗抑郁症方面的整体疗效和证据确定性.
主要方法:
- 对1093名参与者的11项试验进行了系统性审查和随机效应元分析.
- 搜索了四个数据库,直到2025年2月,对与安慰剂比较肌酸的试验进行了搜索.
- 评估偏差风险 (RoB2) 和证据确定性 (GRADE).
主要成果:
- 发现标准化平均差异为-0.34 (95% CI-0.68,-0.00),低于最小重要的差异.
- 发现了大量的异质性 (I2 = 71.3%) 和潜在的偏差.
- 肌酸对缓解有显著影响 (OR 3.60),但没有治疗反应 (OR 0.72).
结论:
- 肌酸可以为抑郁症提供小到中等的益处,但平均效果在临床上并不重要.
- 目前的证据的确定性非常低,这表明真正的影响可能是微不足道或无效的.
- 更大的,高质量的随机试验是必要的,以确定关于肌酸对抑郁症有效性的最终结论.
更多相关视频
10:54Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
Published on: November 21, 2025
271
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
509
相关概念视频
Electroconvulsive Therapy
841
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
841
Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Antidepressant Drugs: MAOIs and Other Agents
791
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
791
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Depression: Overview
763
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
763
